Bristol Myers Squibb
Bristol Myers Squibb (Ticker: NYSE: BMY) is a medicines and science company dating back over 135 years. Starting out by Edward Robinson Squibb who was born on the 4th July 1819 in Wilmington, Delaware, USA.
Edwards aim was to provide high quality standardised medicines after spending 10 years in the navy as a surgeon. A crusader against impure drugs and at request from the government in 1847 he set up a laboratory in a Naval Hospital in Brooklyn New York. In 1852 he starts production of Ether by distillation in a way to provide relief to suffering patients going through operations with no anaesthesia. From here the company structure starts being joined along the way by fellow scientists William McLaren Bristol (1887) & right up to 1989 when both Bristol Myers & Squibb companies merge. The full and extremely interesting history is can be found on their website by clicking here.
Today Bristol Myers Squibb is a global biopharmaceutical company that focuses in the unmet needs of patients with serious diseases.
The company has an array of medicines that are available, unfortunately the list is far too exhaustive to list here, however we have provided a link directly to their website here.
This is why we would deem BMY to be a quality medicines business in that today it focuses in specialist fields like: Oncology, Hematology, Immunology, Cardiovascular & Fibrosis.
Here are ten reasons behind our thesis for an investment case:
1, Global sales annually of $48,300 Billion (31/12/24)
2, Extensive pipeline of drugs in development trials
3, BMY has paid a dividend for over 50 years (Historical dividends can be found here)
4, Gene Therapy is an area of interest with other areas like:
5, Protein Homeostasis
6, Cell Therapy
7, Drug Delivery technology
8, Antibody Drug Conjugates
9, In recent years BMY has been on an acquisition trail, picking up company’s like Celgene in 2019 & MyoKardia in 2020
10, There is a long history of partnerships and collaborations with various companies in developing the next generations of medicines that builds on their heritage in developing blockbuster drugs.
Bristol Myers Squibb average five year share price
The average share price for Bristol Myers Squibb over the last five years (11/08/2019 to 08/08/2024) sits between:
At the lowest point the stock was valued at $39.35 on the 7th July 2024.
To the highest valuation point of $81.44 on the 12th April 2022.
Based on personal experience and only looking at a long term hold, today we would purchase additional shares between a price ranging from $39.95 to $45.00.
An ideal exit strategy would be to hold for 10-15 years with a sell price between $85-$95 dollars.
Using such a time frame would allow for new drugs to be approved which in turn should hopefully increase revenues and profits.
Concerns regarding the expiry of certain patents that could erode sales and profits around the 2030 mark is always a case of concern for medicines manufacturers. BMY have not been resting on their laurels though, as they have been on a spending spree over the last few years, which has been a familiar theme for other pharmaceutical manufacturers that are in similar patent cliff situations.
Our investment case remains the same and we will continue to hold BMY in the portfolio with a long term view.
Bristol Myers Squibb Dividend
Bristol Myers Squibb distributes a quarterly dividend usually in the months of February, May, August and November. BMY’s annual dividend has increased for the last 17 years.
Quarter three’s most recent dividend was $0.62 cents (Ex Dividend on 03/07/2025) or $2.48 dollars annualised.
For research purposes we have listed the last eleven years of annual payments below:
2024 $2.40
2023 $2.28
2022 $2.16
2021 $1.96
2020 $1.80
2019 $1.64
2018 $1.60
2017 $1.56
2016 $1.52
2015 $1.48
2014 $1.44
BMY current fundamentals:
P/E: 18.55% (01/08/2025)
Fwd P/E: 7.10% (01/08/2025)
Dividend yield is 5.40% (01/08/25)
We have held this equity for five years (20 quarters) at a starting quantity of 65 shares, increasing the holding to 90 shares at the end of 2023.
When funds allow we aim to increase the shares 110 in the next 18 months.
Total dividend income for Bristol Myers Squibb to date is £651.29
Further income analysis can be viewed in the file below:
BMY
Please remember that all investments can rise and fall in value, therefore you may get back less then you originally invested.
This website or webpage is not a suggestion to purchase or invest in any stocks / equities and is presented purely for research analysis.
Should you be unsure of any investment whether it be purchasing shares or equities directly, funds or investment trackers, you should seek independent financial advice from a qualified financial advisor.
All logos and Trademarks are the property of the company covered in this article. We only use logos/pictures to assist investors identify the Brand/s and encompassing products.
